Article Abstract

FOLFOX plus cetuximab in first-line therapy of advanced colorectal cancer

Authors: Roland Ehrenberg, Niels Halama


Oxaliplatinum is derivate of platinum, which has been used for colorectal cancer since 1997 in France for first-line therapy of metastatic colorectal cancer. Following the data from the MOSAIC trial (1), oxaliplatinum-based adjuvant therapy was established. Development of the oxaliplatinum-based protocols lead to the development of FOLFOX4 (2) and FOLFOX6 (3) and subsequent FOLFOX7 protocols (4).